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Abstract Intracellular activation of sphingomyelinase, leading 
to ceramide generation, and ICE-like proteases have been 
implicated in TNF and Fas-indnced apoptosis, hut the links 
between these intracenular apoptotic mediators remain unde- 
f'med. We show here that a specific peptide inhibitor of the ICE- 
like protease CPP321Yama (DEVD-cHO) blocks anti-Fas- 
induced apoptosis in Jurkat and U937 cells, while having no 
effect on TNF-indnced apoptosis in U937 cells. This peptide also 
prevents ceramide accumulation induced by Fas engagement. 
Jurkat and U937 cells, as well as their mtDNA-depleted erived 
lines (po cells), were sensitive to ceramide toxicity, which was not 
prevented by ICE-like protease inhibitors. These results, taken 
together, suggest that ICE-like protease activation is a 
prerequisite for eeramide generation and subsequent apoptosis, 
at least in the case of Fas-indnced cell death. 
e;ey words': Fas; Tumor necrosis factor a;  Ceramide; 
CE-like proteases; Apoptosis 
1. Introduction 
The intracellular delivery of the apoptotic signal transduced 
)y receptors possessing the so-called death domain [1] is 
;~oorly delineated. Recently, the sphingolipid ceramide has 
~een implicated in the apoptosis induced by stimulation of 
::he Fas molecule [2,3] and of tumor necrosis factor (TNF) 
55 kDa receptor [4]. In this model, upon occupancy of recep- 
:or, an intracellular sphingomyelinase would be activated by 
m unknown coupling mechanism, causing hydrolysis of 
~phingomyelin and generation of ceramide [4-6]. Ceramide, 
n its turn, would bind to and activate several Ser/Thr protein 
~inases [7] and phosphatases [8] that would connect with the 
ras/raf/MAP-kinase pathway [9,10]. On the other hand, genet- 
ic research in nematodes has led to the discovery of genes 
which positively and negatively regulate apoptosis. Several 
Cys-proteases, namely the interleukin-ll3 converting enzyme 
(ICE), homologous to the product of Caenorhabditis elegans 
~ed-3 cell death gene, and other ICE-like proteases have been 
implicated in different ypes of apoptosis [11]. In particular, 
Fas-induced apoptosis is inhibited in ICE-knockout mice [12] 
and it is also partially inhibited by a tetrapeptide inhibitor 
(YVAD-cmk) of ICE-like proteases [13]. Moreover, overex- 
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pression of the poxvirus-derived serpin CrmA, which was 
shown to inhibit ICE and other ICE-like proteases [14,15], 
renders cells resistant to Fas- or TNF-induced apoptosis 
[13,15 17]. However, the precise sites of action of ICE-like 
proteases in the apoptotic pathway are not known. 
We have analyzed here the effect of peptide inhibitors of 
ICE-like proteases on TNF-, Fas- and ceramide-induced 
apoptosis. Results indicate that Fas-induced apoptosis and 
ceramide generation were prevented by DEVD-cuo, a specific 
inhibitor of the ICE-like protease CPP32/Yama, demonstrat- 
ing that its activation precedes phingomyelin breakdown in 
the apoptotic pathway. 
2. Materials and methods 
2.1. Materials 
N-Acetyl-Tyr-Val-Ala-Asp-chloromethylketone (YVAD-cmk) and 
N-acetyl-Asp-Glu-Val-Asp-aldehyde (DEVD-cr~o), were from Bachem 
(Switzerland) and Novosystem (France). Neutral sphingomyelinase 
from Staphylococcus aureus, C2-ceramide and ceramide type III, 
from bovine brain, ethidium bromide, 3-[4,5-dimethylthiazol-2-yl]- 
2,5-diphenyl-tetrazolium bromide (MTT), dimethyl sulfoxide 
(DMSO) and dodecane were products from Sigma (Spain). Human 
recombinant TNF-a was kindly provided by The National Biological 
Standards Board (UK). Mouse monoclonal nti-human Fas IgM anti- 
body (clone CH-I 1) was from UBI (Lake Placid, USA). 
2.2. Cell culture 
Human promonocytic leukemia U937 and Jurkat T-cell leukemia 
(ATCC, clone E6.1) were routinely cultured at 37°C in RPMI 1640 
medium (Biowhittaker, Spain) supplemented with 5% fetal calf serum 
(hereafter, complete medium), using standard cell culture procedures. 
Two sublines devoid of functional mitochondria (p° cells) were gen- 
erated from U937 and Jurkat cells by long-term culture in the pres- 
ence of 50 ng/ml of ethidium bromide which selectively eliminates 
mtDNA, as described previously [18]. Selection and culture medium 
of U937-p ° and Jurkat-p ° cells was also supplemented with glucose 
(4.5 mg/ml), sodium pyruvate (0.1 mg/ml) and uridine (50/ag/ml). The 
elimination of mtDNA in p° cells was monitored by PCR using spe- 
cific primers, as previously described [18]. After selection for 40 weeks, 
130 cells were entirely devoid of mtDNA and ethidium bromide was 
eliminated from culture media. One year after the establishment of 
mtDNA-depleted cell lines, no reversion to the p + phenotype has been 
observed. 
2.3. Cell proliferation assays 
U937 and Jurkat cells were seeded in flat-bottom, 96-well plates at 
an initial density of 2 × 10 n cells/ml (100/al/well), were cultured for 16- 
20 h in complete medium or in medium containing either anti-Fas 
antibody (5-100 ng/ml), TNF (5-100 U/ml), C2-ceramide (10 /aM) 
or natural (C18) ceramide (50-200 nM) and were first dissolved in 
ethanol:dodecane (98:2, v/v), and then added to serum-free culture 
medium (RPMI 1640:DMEM:Ham's F12, 2:1:1) as indicated in [19]. 
At the doses used, ethanol and dodecane had no effect on cell pro- 
liferation. The effect of the protease inhibitors YVAD-cmk and/or 
DEVD-cHo (300-600 /aM) on TNF-, Fas- and ceramide-induced 
apoptosis was also evaluated, Peptide inhibitors were added to cul- 
tures dissolved in DMSO, the final DMSO concentration being 
-<0.4% (v/v). The addition of YVAD or DEVD to cell cultures at 
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concentrations up to 1.2 mM did not affect to the growth rate, cell 
morphology and Fas expression i  Jurkat and U937 cells. Cells were 
preincubated for 3 h with the protease inhibitors before adding the 
toxic stimuli to assure a sufficient incorporation by cells [13]. Cell 
viability was determined by a modification of the MTT reduction 
method of Mosmann [20] and expressed as percent of the correspond- 
ing control cells. 
2.4. Fluorescence microscopy 
Morphological evaluation of the degree of apoptosis was performed 
by labelling cells with the nuclear stain p-phenylenediamine (PPDA) 
and visualization by fluorescence microscopy [21]. After incubation in 
the conditions described in each case, cells were collected, washed with 
phosphate-buffered saline, pH 7.4 (PBS) and fixed at room tempera- 
ture with 1% paraformaldehyde in PBS for 15 min. Fixed cells were 
washed with PBS, centrifuged onto glass coverslips in wells of a 24- 
well plate and mounted on a glass slide over a drop of PPDA stain (10 
mg of PPDA in 1 ml PBS mixed with 9 ml of oxidized glycerol) [22]. 
2.5. Analys& of ceramide production 
Jurkat cells (6× l0 s in 10 ml) were labelled for 48 h with 5 laCi of 
[1-14C]stearic a id bound to fatty acid-free serum albumin (1:1, molar 
ratio) in complete medium. Cells were then harvested and resuspended 
in complete medium at 4 × 105 cells/ml. Prior to the addition of anti- 
Fas, cells were pretreated with 600 ~tM DEVD-cHo or with the appro- 
priate amount of DMSO (controls) for 3 h [13]. Anti-Fas antibody (at 
20 ng/ml) was added and cells were incubated for another 17 h. Then, 
cells were harvested, washed with cold RPMI medium and counted. 
Cell viability was determined in an aliquot of the corresponding cell 
suspensions by the MTT assay. Total cell lipids were extracted at 4°C 
with chloroform/methanol 2/1 (v/v) [23]. Radioactivity content of ali- 
quots from CHCI3 phases was determined by liquid scintillation 
counting and equal amounts of radioactivity in each sample were 
applied to thin-layer chromatography (TLC) Silica gel G plates 
(Scharlau, Spain). Plates were pre-washed with chloroform/methanol 
(l/l, v/v) and heat-activated at 110°C for 1 h. A first development of
TLC-loaded samples was performed with chloroform/methanol/water 
(60/30/5, v/v) up to 10 cm from the bottom of the plate and a second 
development to its full length with hexane/diethyl ether/acetic a id (80l 
20/2, v/v). Plates were air-dried and radiolabelled bands located by 
film autoradiography (Hyperfilm [3-max, Amersham) at room tem- 
perature for 2 3 days. Then, sample lanes were covered with glass, 
allowing the marker lanes to be iodine-stained. Authentic standards of 
ceramide, sphingomyelin, cholesterol, phosphatidylcholine and phos- 
phatidylserine (Sigma) were used as markers. Bands were scraped and 
transferred to vials, to which 4 ml of scintillation cocktail (Normas- 
cint 11, Scharlau), containing 10% (v/v) methanol, was added. Radio- 
activity in samples was determined by liquid scintillation counting. 
3. Results and discussion 
3.1. Effect of ICE-like protease inhibitors on TNF- and 
Fas-induced apoptosis 
The peptide chlorometylketone YVAD-cmk, developed in- 
itially as an irreversible ICE inhibitor [24], can also inhibit 
CPP32 and perhaps other ICE-like proteases, at least in in 
vitro cell-free assays [25]. The aldehyde DEVD-cHo, however, 
has been proved to be a specific inhibitor of the ICE-like 
protease CPP32, responsible for the cleavage of the apopto- 
sis-related protein poly(ADP-ribose) polymerase (PARP) [26]. 
We have used these inhibitors to study the implication of ICE- 
like protease in Fas-induced apoptosis of sensitive Jurkat cells 
[27]. Overnight incubation with anti-Fas antibody at 5 and 10 
ng/ml induced 50% and 75% cell death, respectively (Fig. la). 
Toxicity caused by anti-Fas at 5 ng/ml was eliminated by 
YVAD-crnk (Fig. la). However, and like the report by Enari 
et al. [13], at a higher anti-Fas concentration, the protection 
offered by YVAD-cmk (600 ~tM) was only partial (Fig. la). 
Using the specific CPP32 inhibitor DEVD-cHo in our in vivo 
assay, and contrary to results obtained with YVAD-cmk, we 
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Fig. 1. Effect of ICE-like protease inhibitors on Fas- and TNF-in- 
duced cytotoxicity. Jurkat (a) or U937 (b) cells were preincubated 
at 37°C for 3 h in either control medium, or in medium supplemen- 
ted with a 600 taM concentration of either YVAD-cmk, DEVD-cHo, 
or both. Then, anti-Fas (a), and TNF (45 U/ml) or anti-Fas (10 ng/ 
rnl) (b), were added and cells incubated for 16 h (anti-Fas) or 24 h 
(TNF). Cell viability was determined by the MTT assay and ex- 
pressed as percentage of the values of appropriate controls in each 
experimental condition. Data are the mean + S.D. of 4 different de- 
terminations. Significant differences from controls are indicated. 
*P < 0.05; **P < 0.005; ***P < 0.0005. 
found a very efficient protection from anti-Fas-induced toxic- 
ity on Jurkat cells, at both concentrations tested (Fig. la). 
Indeed, CPP32 has recently been characterized as the main 
ICE-like protease implicated in Fas-induced eath in Jurkat 
cells [28]. Fas and the 55 kDa TNF  receptor belong to the 
same family of surface receptors, both express death domains 
in their cytoplasmic tails, and it has been proposed that they 
could share the death-inducing mechanism [1]. To study the 
effect of peptide inhibitors on TNF-induced toxicity we used 
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the TNF- and Fas-sensitive U937 cells, since Jurkat cells are 
not killed by TNF (data not shown and [29]). As shown in 
Fig. lb, TNF toxicity was not prevented by YVAD-cmk. 
DEVD-cHo offered only a slight protection, not improved 
by the combination with YVAD-cmk (Fig. lb). Treatment 
ot ~ U937 cells with anti-Fas at 10 ng/ml induced 55% cell 
death, which was not prevented by YVAD-cmk, while 
DEVD-cHo alone or in combination with YVAD-cmk offered 
s~gnificant protection (Fig. lb). Similar results have been ob- 
t:dned for Fas-based cytotoxicity exerted by T cell effectors on 
1 r937, U937-p ° and L1210Fas cells [22]. These results suggest 
timt, although TN-F and Fas-induced apoptosis could share 
some biochemical steps, the pathways induced by both recep- 
l)rs should differ beyond a given point. Previous studies have 
~ emonstrated that CrmA, a cowpox virus-derived serpin, can 
i lhibit both TNF- and Fas-induced apoptosis [15,16]. CrmA 
i lhibits ICE [14], and it also inhibits PARP cleavage after Fas 
r TNF receptor engagement [15]. PARP is not a substrate 
l~r ICE [25], while it is a good substrate for CPP32 protease 
~ctivity [15,26]. These results uggested that CrmA blocking of 
t oth TNF- and Fas-induced apoptosis was mediated by in- 
I ibition of CPP32 activation [15]. By using DEVD-cHo, the 
~irect implication of CPP32 in Fas-induced cytotoxicity is 
,iemonstrated in the present and a previous study from our 
vroup [22]. Our results also suggest hat TNF toxicity could 
i,e mediated by a CrmA-inhibitable protease different from 
;PP32. 
To analyze the effect of DEVD-cHo on morphological 
~.hanges induced in Jurkat cells by treatment with anti-Fas 
~mtibody, cells were incubated with anti-Fas and/or DEVD, 
tained with PPDA and analyzed by fluorescence microscopy. 
\nti-Fas induced in Jurkat cells the typical features of apop- 
osis, including cell shrinkage, chromatin condensation and 
,xtensive nuclear fragmentation (Fig. 2A). However, viability 
:.nd aspect of cells treated with anti-Fas in the presence of 
)EVD-cHo was similar to controls and no sign of nuclear 
ragmentation was detected (Fig. 2B). U937 cells treated 
vith TNF also showed extensive nuclear fragmentation, that 
vas not prevented by either DEVD-cHo, or the combination 
ff YVAD-cmk and DEVD-cHo (data not shown). 
~.2. mtDNA depleted cell lines are sensitive to 
ceramide-induced apoptosis 
We have previously shown that mitochondrial chain inhibi- 
ors or a great reduction in mtDNA content did not prevent 
FNF and anti-Fas toxicity on U937 cells [18], demonstrating 
hat neither TNF nor Fas-induced toxicity is dependent on 
ntact mitochondrial function. Additionally, U937-9 ° cells lose 
he expression of the 55 kDa TNF receptor and were no long- 
~'r sensitive to TNF [18], while in Jurkat-p ° cells membrane 
Fas expression was impaired (data not shown). Sphingomye- 
inase activation and ceramide generation seem to be a com- 
non event in TNF- and Fas-induced cytotoxicity [24]. We 
:ested therefore if p° cells were sensitive to ceramide toxicity. 
gynthetic (C2) or natural (Cls) ceramide substantially inhib- 
ted the growth of normal or 9 ° cells after overnight treatment 
Fig. 3A). Quantitative differences in the level of toxicity in- 
duced by synthetic or natural ceramide were also observed, as 
~hown in Fig. 3A, demonstrating the importance of ceramide 
hydrophobicity in its function, as already suggested [19]. 
Fhese results indicate that in spite of the loss of Fas and 
FNF receptor expression in 9 ° cells, the ceramide-activated 
A 
[3 
Fig. 2. Fas-induced apoptosis prevented by CPP32 inhibition. Jur- 
kat cells were treated with anti-Fas (10 ng/ml), as indicated in the 
legend of Fig. 1, in the absence (A) or in the presence (B) of 600 
~tM DEVD-cHo. Cell nuclei were stained with PPDA and photo- 
graphed under epifluorescence illumination. Original magnification, 
× 400. 
pathway is intact, and mitochondrial function is not needed 
for ceramide-induced apoptosis. 
Treatment with exogenous ceramide caused morphological 
features of apoptosis, such as cell shrinkage and nuclear con- 
densation in U937 (Fig. 3B) as well as in U937-p ° cells (Fig. 
3C). However, and contrasting with the extensive nuclear 
fragmentation observed after anti-Fas treatment of Jurkat 
cells (Fig. 2A) or TNF treatment of U937 cells [21], ceramide 
induced a more limited nuclear fragmentation (Fig. 3B,C). 
Similar results were obtained when comparing normal Jurkat 
to Jurkat-p ° cells (data not shown). This result suggests that 
extensive nuclear fragmentation is mainly dependent on recep- 
tor-generated signals other than ceramide production. Never- 
theless, nuclear fragmentation is a dispensable event at least in 
Fas-induced apoptosis [30]. 
3.3. ICE-like protease inhibitors do not prevent 
ceramide-induced apoptosis 
The involvement of sphingomyelinase activation in Fas- 
and TNF-induced apoptosis is well established [4-6]. Our 
present data support he previously proposed role of CPP32, 
at least in Fas-based cytotoxicity [15]. The possibility that 
sphingomyelinase activation and ceramide generation could 
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lead by a still unidentified mechanism to the activation of 
ICE-like proteases was explored using U937, Jurkat, and their 
corresponding p°-derived cells. If this was true, ICE-like pro- 
tease inhibitors hould prevent ceramide toxicity. However, as 
shown in Fig. 3A, ceramide toxicity on all cell types tested 
was not inhibited by DEVD-cHo, at concentrations that com- 
Fig. 3. Ceramide-induced apoptosis in Jurkat, U937 and p°-derived 
cell lines is not prevented by DEVD-cHO. Top: In A, cells were pre- 
incubated for 3 h either in control medium or in medium containing 
600 I.tM DEVD-cno. Then, 10 ktM C2-ceramide or 200 nM Cls-cer- 
amide, dissolved in ethanol/dodecane 98/2 (v/v), was added and cells 
were incubated for another 16 h. Final concentration of ethanol/do- 
decane was 0.4% (v/v). Cell viability was determined by the MTT 
assay and data are the mean+S.D, of 4 different determinations. 
Bottom: Fluorescence micrographs of cells treated for 16 h with 
200 nM Cls-ceramide and stained with PPDA. B: U937 cells; C: 
U937-9 ° cells. 
<-- 
pletely blocked anti-Fas induced toxicity on U937 and Jurkat 
cells (Fig. la, Fig. 2). Moreover, DEVD-cHo did not prevent 
the toxicity caused by the addition to cultures of bacterial 
sphingomyelinase (data not shown). 
3.4. Blocking of anti-Fas-induced ceramide generation by 
DEVD 
The finding that DEVD-cHo did not block ceramide-in- 
duced cell death, while it did block Fas-induced apoptosis, 
suggested that ICE-like protease activation could be an event 
upstream of sphingomyelinase activation after Fas engage- 
ment. To test this possibility, we analysed the effect of 
DEVD-cHO on Fas-induced ceramide generation. Jurkat cells 
were labelled with [1-14C]stearic a id for 48 h and treated with 
anti-Fas antibody in the presence or absence of DEVD-cHO. 
Cellular lipids were then extracted, separated by TLC and 
relative levels of ceramide determined as indicated in Section 
2. Anti-Fas treatment induced a 2-fold increase in the cera- 
mide to cholesterol ratio and a 2.6-fold increase in the cera- 
mide to sphingomyelin ratio, relative to control cells (Fig. 4). 
Data were also expressed as ceramide to cholesterol ratio 
since preliminary experiments indicated that cholesterol label- 
ling remained unchanged, irrespectixre of cell treatments. Re- 
markably, DEVD-cHo completely abolished the increase in 
endogenous ceramide content induced by Fas engagement 
(Fig. 4). Similar results were obtained when the levels of cer- 
amide were normalised to the cell phospholipid content, as 
determined by a modified Bartlett's assay [23] (data not 
shown). In these experiments, the extent of cell death caused 
by anti-Fas, as monitored by the MTT assay, was around 70% 
and the protection offered by DEVD-cHo was complete. A 
similar and parallel increase in ceramide generation and cell 
death has been recently found in rat SKW6.4 cells treated 
with anti-Fas [3]. It is also worth noting that the kinetics of 
Fas-mediated ceramide generation [3] parallels that of PARP 
cleavage [15]. 
Sphingomyelinase and ICE-like protease activation have 
been implicated in several forms of apoptosis and especially 
in those induced by TNF and Fas [2-5,12,13,15-17,31]. How- 
ever, the connection between both signalling pathways had 
not been characterised. Our present results indicate that 
ICE-like protease(s) activation after Fas engagement is lo- 
cated upstream of sphingomyelinase activation/ceramide gen- 
eration in human cells. In this respect, it has been recently 
reported that reaper-induced cell death and ceramide genera- 
tion in insect cells are prevented by ICE-like protease inhibi- 
tors [32]. The reaper protein from Drosophila contains a death 
domain and is a homologue of the mammalian 55 kDa TNF 
receptor and Fas [33]. 
It has been suggested that Fas-induced ceramide generation 
may be mediated by an acidic sphingomyelinase [2]. However, 
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i,at cells. Jurkat cells previously labelled with [1-14C]stearic acid 
vere incubated for 3 h in the presence or absence of DEVD-cIJo, as 
adicated. Then, anti-Fas (20 ng/ml) was added and after incubation 
or  another 16 h, cell lipids were separated by thin-layer chromatog- 
aphy, and radioactivity associated with ceramide (Cer), sphingo- 
nyelin (SM) and cholesterol (Chol) determined as indicated in See- 
ion 2. Results are expressed as the ratio of radioactivity in the 
. eramide to cholesterol fractions or ceramide to sphingomyelin frac- 
ions. Data are the mean + S.D. of 34  different experiments. Radio- 
tctivity recovered in Cer, SM and Chol fractions was greater than 
~00, 5000 and 1300 cpm, respectively. 
mother recent and more detailed report demonstrate that 
:eramide production after Fas engagement is dependent on 
leutral, and not on acidic, sphingomyelinase [3]. Since cera- 
nide generation by neutral sphingomyelinase takes place pre- 
mmably at the plasma membrane [4], the present demonstra- 
;ion of CPP32-mediated ceramide generation would suggest a
:lose membrane localisation for this protease. In this respect, 
t has been reported that ICE is located at the plasma mem- 
,9rane in human monocytes [34]. If CPP32 was also a mem- 
.9rane-associated protein, it could be activated early after Fas 
:rosslinking and the subsequent cleavage of an unidentified 
mbstrate would, in turn, stimulate sphingomyelinase. The pre- 
-ise cellular location of CPP32 and the molecular mechanism 
"or CPP32-induced sphingomyelinase activation are not 
.<nown. In any case, in the present work we demonstrate a 
:lose interrelationship between both death-inducing pathways, 
i t  least in Fas-induced apoptosis. 
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